Crizotinib

What is Crizotinib?

Crizotinib is a prescription medication used in the treatment of specific types of non-small cell lung cancer (NSCLC). It belongs to a class of drugs known as protein kinase inhibitors and is considered a targeted therapy. Unlike traditional chemotherapy, which broadly attacks rapidly dividing cells, Crizotinib is designed to specifically interfere with molecules involved in the growth and spread of cancer cells that have certain genetic alterations. It is primarily known for its effectiveness in patients with ALK-positive non-small cell lung cancer and ROS1-positive non-small cell lung cancer.

First approved by the FDA in 2011, Crizotinib is marketed under the brand name Xalkori. Its development marked a significant advancement in personalized medicine for lung cancer, offering a more precise and often more effective treatment option for patients whose tumors harbor the specific genetic rearrangements it targets.

How Does it Work?

Crizotinib functions as a multi-targeted receptor tyrosine kinase inhibitor. Its primary mechanism of action involves blocking the activity of the anaplastic lymphoma kinase (ALK) and ROS1 proto-oncogene receptor tyrosine kinase proteins. In healthy cells, these kinases play a role in normal cell growth and development. However, in certain cancer cells, genetic rearrangements (fusions) can lead to these kinases becoming overactive or constitutively active, driving uncontrolled cell proliferation and tumor growth.

By binding to and inhibiting these abnormal ALK and ROS1 fusion proteins, Crizotinib effectively interrupts the signaling pathways that fuel cancer cell survival and division. This disruption leads to a reduction in tumor size or a slowing of cancer progression. The specificity of Crizotinib for these mutated proteins is what makes it a targeted therapy, allowing it to attack cancer cells while minimizing harm to healthy cells, compared to conventional chemotherapy.

Medical Uses

The primary medical use of Crizotinib is for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are characterized by specific genetic alterations. These include:

• ALK-positive NSCLC: Crizotinib is approved for the treatment of patients with metastatic NSCLC whose tumors are ALK-positive, as detected by an FDA-approved test. It can be used as a first-line treatment or in patients who have progressed on other therapies.
• ROS1-positive NSCLC: It is also indicated for the treatment of patients with metastatic NSCLC whose tumors are ROS1-positive, as detected by an FDA-approved test.

These specific indications underscore the importance of genetic testing (biomarker testing) in NSCLC patients to determine if their cancer has the ALK or ROS1 rearrangement, as Crizotinib will only be effective in those with these particular mutations. The drug has significantly improved outcomes for these specific subsets of lung cancer patients, often leading to longer progression-free survival compared to traditional chemotherapy.

Dosage

The standard recommended dosage of Crizotinib for adult patients is 250 mg taken orally twice daily, approximately every 12 hours. It can be taken with or without food. It is crucial to swallow the capsules whole and not to crush, dissolve, or open them.

Treatment with Crizotinib typically continues as long as the patient is deriving clinical benefit and tolerating the medication. The prescribing physician will monitor the patient's response and manage any side effects. Dose adjustments may be necessary based on the patient's tolerance to the drug, particularly in cases of severe side effects like liver toxicity, gastrointestinal issues, or vision problems. Dose reductions or temporary interruptions may be implemented, but patients should never adjust their dosage without consulting their healthcare provider. Regular monitoring of blood counts, liver function, and vision is essential during treatment.

Side Effects

Like all medications, Crizotinib can cause side effects, ranging from mild to severe. It is important for patients to discuss any new or worsening symptoms with their doctor.

Common Side Effects:

• Nausea, vomiting, diarrhea, or constipation
• Vision disorders (e.g., blurred vision, double vision, flashes of light, sensitivity to light)
• Edema (swelling), particularly in the hands, feet, and face
• Fatigue
• Decreased appetite
• Dizziness
• Neuropathy (numbness or tingling in hands or feet)

Serious Side Effects:

• Hepatotoxicity (Liver Problems): Severe and potentially fatal liver injury can occur. Patients require regular liver function tests.
• Interstitial Lung Disease (ILD)/Pneumonitis: Severe, life-threatening, or fatal ILD/pneumonitis can occur. Symptoms include shortness of breath, cough, and fever.
• Bradycardia (Slow Heart Rate): Crizotinib can cause a slow heart rate.
• QTc Prolongation: This heart rhythm abnormality can lead to serious arrhythmias. ECG monitoring may be required.
• Vision Loss: Cases of severe vision loss, including permanent vision loss, have been reported.
• Gastrointestinal Perforation: Rarely, holes in the stomach or intestine can occur.

Patients should seek immediate medical attention if they experience severe abdominal pain, sudden shortness of breath, yellowing of the skin or eyes, or significant changes in vision.

Drug Interactions

Crizotinib is metabolized by the enzyme CYP3A in the liver, making it susceptible to interactions with other drugs that affect this enzyme. Important drug interactions include:

• Strong CYP3A Inhibitors: Co-administration with strong CYP3A inhibitors (e.g., ketoconazole, itraconazole, clarithromycin, ritonavir, grapefruit juice) can increase Crizotinib concentrations, potentially leading to increased side effects. Concomitant use should be avoided or managed with dose reduction.
• Strong CYP3A Inducers: Co-administration with strong CYP3A inducers (e.g., rifampin, phenytoin, carbamazepine, St. John's wort) can decrease Crizotinib concentrations, potentially reducing its effectiveness. Concomitant use should generally be avoided.
• Drugs that Prolong QT Interval: Crizotinib itself can prolong the QTc interval. Co-administration with other medications known to prolong the QTc interval (e.g., antiarrhythmics, certain antipsychotics, some antibiotics) should be approached with caution due to an increased risk of cardiac arrhythmias.
• CYP3A Substrates: Crizotinib can inhibit CYP3A, potentially increasing the concentrations of other drugs that are primarily metabolized by CYP3A.

It is crucial for patients to inform their healthcare provider about all medications, supplements, and herbal products they are currently taking to avoid potentially dangerous interactions.

FAQ

Q: Is Crizotinib a form of chemotherapy?

A: No, Crizotinib is not chemotherapy. It is a targeted therapy, which means it specifically targets certain genetic mutations (ALK or ROS1 rearrangements) found in cancer cells, rather than broadly attacking all rapidly dividing cells like traditional chemotherapy.

Q: How long do patients typically take Crizotinib?

A: Patients typically continue taking Crizotinib for as long as the medication is effective in controlling their cancer and as long as they can tolerate its side effects. The duration of treatment varies significantly among individuals.

Q: What does ALK-positive NSCLC mean?

A: ALK-positive NSCLC refers to a subtype of non-small cell lung cancer where the cancer cells have a specific genetic rearrangement involving the Anaplastic Lymphoma Kinase (ALK) gene. This rearrangement leads to the production of an abnormal ALK protein that drives cancer growth, making it a target for drugs like Crizotinib.

Products containing Crizotinib are available through trusted online pharmacies. You can browse Crizotinib-based medications at ShipperVIP or Medicenter.

Summary

Crizotinib represents a significant advancement in the treatment landscape for specific subsets of non-small cell lung cancer. As a targeted therapy and kinase inhibitor, it precisely acts on abnormal ALK and ROS1 fusion proteins, offering a more personalized and often more effective approach for patients whose tumors harbor these genetic rearrangements. While highly effective for its intended use, patients must be closely monitored for potential side effects, including serious ones affecting the liver, lungs, and heart. A thorough understanding of its mechanism, uses, and potential interactions, alongside diligent medical supervision, is key to optimizing outcomes for patients undergoing Crizotinib treatment.